Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

R.E. van Genugten, D.H. van Raalte, M. Diamant

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)S26-S34
JournalDiabetes Research and Clinical Practice
Volume86
DOIs
Publication statusPublished - 2009

Cite this